Daewoong Pharmaceutical's Fexuclue is expanding globally as fast as it is effective.Daewoong said Friday that its gastroesophageal reflux disease (GERD) treatment, Fexuclue, has entered or is about to enter the market in 24 countries, including Korea, in just one year and six months since its launch
JW Pharmaceutical said Wednesday that the U.S. Drug Safety Monitoring Board (DSMB) has positively reviewed top-line results from its multinational phase 3 clinical trial of Epaminurad (codenamed URC102) for gout and recommended continuing the trial.On Jan. 31, the DSMB, comprised of U.S. rheumatolog
The management conflict between Hanmi Science, the Hanmi Pharmaceutical Group holding company, and Lim Jong-yoon, the eldest son of the late founder and president of Hanmi Pharmaceutical, is deepening.After Hanmi Science criticized Lim, the latter hit back."Hanmi Pharm's public relations team claims
Celltrion is expanding its market presence in Peru, a key Latin American market, with successful public tender wins.Celltrion’s Truxima 500mg (rituximab) won the tender for the Peruvian Ministry of Health (Centro Nacional de Abastecimiento de Recursos Estratégicos en Salud, CENARES), the largest pub
Dong-A ST and IMBiologics said they have entered into a research collaboration agreement to develop a novel antibody drug candidate.The collaboration involves IMBiologics deploying its ePENDY (enhanced/engineered Pentamer body) platform technology.Unlike the conventional IgG antibody-based modalitie
Sanofi-Aventis Korea has extended the expiration date of its hemophilia A treatment Eloctate (efmoroctocog alfa) in Korea, following a controversy over mislabeling the drug's expiration date.Sanofi said Wednesday that it has received approval from the Ministry of Food and Drug Safety (MFSD) to exten
New drugs with different mechanisms of action have recently entered the ulcerative colitis (UC) treatment market in Korea, heralding fierce competition.Last Friday, the Ministry of Food and Drug Safety (MFDS) approved Lilly's interleukin-23 (IL-23) inhibitor Omvoh (mirikizumab), giving Korean patien
SK chemicals said that it has decided not to proceed with the sale of its pharmaceutical business unit despite having previously signed a non-binding memorandum of understanding (MOU) with Glanwood Private Equity.SK chemicals' business divisions are divided into green chemicals, which produces eco-f
Huons' sales exceeded 500 billion won ($375 million) last year, thanks to increased pharmaceutical exports and efficient management of sales and management expenses.In a public filing on Wednesday, the company disclosed its preliminary consolidated operating results for 2023.According to the disclos
After posting strong growth last year, Boryung aims to continue its momentum this year and join the “Trillion Won Club.” The company's confidence is fueled by increased sales across all business areas and success in the anticancer area.Boryung CEO Chang Doo-hyun (Daniel Chang) recently met with repo
In a notable legal development, Hugel has secured a favorable outcome in its legal battles against the Ministry of Food and Drug Safety (MFDS) regarding the indirect export of Botulax, its botulinum toxin (BTX) products, which led to the revocation of its sales license. The Seoul Administrative Cour
Many Korean pharma and biotech companies posted record-breaking results last year. Still, those focusing on the vaccine business, including GC Biopharma and SK bioscience, performed relatively poorly as the Covid-19 pandemic eased to an endemic.According to GC Biopharma’s preliminary consolidated op
"Taking Sugatree is like catching two birds with one stone, as it offers both ease of administration and cost-effectiveness."Dong-A ST's employees at the Diabetes Division of the Marketing 2 team of the ETC Business Headquarters said so in unison.Sugatree XR Tablet is a diabetes treatment combinatio
Hanmi Pharm CEO Lim Jong-yoon, the eldest son of the late Lim Sung-ki, who founded the Hanmi Pharmaceutical Group, and his younger, Hanmi Science CEO Lim Jong-hoon, have announced their intention to change the management of Hanmi Science.They plan to form a new board of directors through the shareho
Handok said it decided to establish a local joint venture with Swedish Orphan Biovitrum (Sobi), a global biopharmaceutical company specializing in rare diseases, in the first half of this year.Sobi is a global biopharmaceutical company specializing in rare diseases, providing innovative treatments i
JW Pharmaceuticals announced on Tuesday that interim results from a study showcasing the efficacy and safety of Hemlibra (emicizumab) in hemophilia A patients younger than one year old were recently published in the international journal Blood.Dr. Steven Pipe, professor of pediatrics at the Universi
Hugel said it showcased new clinical findings for its botulinum toxin (BTX) product at the 25th International Master Course on Aging Science (IMCAS) World Congress, held in Paris, France, from Feb. 1 to 3.The event, which is recognized as the world's largest conference on aesthetic plastic surgery,
Tevimbra (tislelizumab), an anti-PD-1 immunotherapy developed by BeiGene, has begun the process of seeking reimbursement in Korea.BeiGene's stance of supplying innovative new drugs at reasonable prices is drawing attention to whether it could alleviate the growing financial burden caused by high-pri
Yuhan Corp. will hold its annual shareholders' meeting next month and decide whether to reappoint Cho Wook-je as its president and CEO. Industry officials watch with interest whether Cho will serve another term.The company issued a public notice last Tuesday, announcing that it would hold its annual
A new treatment has landed in Korea for moderate to severe active ulcerative colitis that has not responded adequately to standard treatments or biologics or has become unresponsive.Lilly Korea said Thursday that the interleukin-23 (IL-23) inhibitor Omvoh (mirikizumab) has received approval from the